ArticleJournal of the National Cancer Institute2013
Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level.
Article in Journal of the National Cancer Institute, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Exploring transposable elements: new horizons in cancer diagnostics and therapeutics.Mobile DNA · 2025Review
- Prolonged culturing of colonic epithelial organoids derived from healthy individuals and ulcerative colitis patients results in the decrease of LINE-1 methylation level.Scientific reports · 2024Article
- The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities.Gut microbes · 2023Review
- Review
- The comparison of risk factors for colorectal neoplasms at different anatomical sites.International journal of colorectal disease · 2023Article
- Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer.Viruses · 2021Article
- Propofol postpones colorectal cancer development through circ_0026344/miR-645/Akt/mTOR signal pathway.Open medicine (Warsaw, Poland) · 2021Article
- Risk Factor Profiles Differ for Cancers of Different Regions of the Colorectum.Gastroenterology · 2020Article
- Utility of inverse probability weighting in molecular pathological epidemiology.European journal of epidemiology · 2018Article
- LINE-1 hypomethylation is not a common event in preneoplastic stages of gastric carcinogenesis.Scientific reports · 2017Article
- DNA Methylation Identifies Loci Distinguishing Hereditary Nonpolyposis Colorectal Cancer Without Germ-Line MLH1/MSH2 Mutation from Sporadic Colorectal Cancer.Clinical and translational gastroenterology · 2016Article
- Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.BMC cancer · 2016Article
- Genomics, Telomere Length, Epigenetics, and Metabolomics in the Nurses' Health Studies.American journal of public health · 2016Review
- Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.Oncotarget · 2016Article
- LINE-1 in cancer: multifaceted functions and potential clinical implications.Genetics in medicine : official journal of the American College of Medical Genetics · 2016Review
- Statistical methods for studying disease subtype heterogeneity.Statistics in medicine · 2016Article
- Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer.International journal of molecular sciences · 2015Review
- Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Review
- Article
- Familial colorectal cancer type X: genetic profiles and phenotypic features.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundBeyond known familial colorectal cancer (CRC) syndromes, the mechanisms underlying the elevated CRC risk associated with CRC family history remain largely unknown. A recent retrospective study suggests familial clustering of CRC with hypomethylation in long interspersed nucleotide element 1 (LINE-1). We tested the hypothesis that CRC family history might confer a higher risk of LINE-1 methylation-low CRC.
methodsUsing the Nurses' Health Study and the Health Professionals Follow-up Study, we prospectively examined the association between CRC family history and the risk of rectal and colon cancer (N = 1224) according to tumor LINE-1 methylation level by duplication method Cox proportional hazards regression. We examined microsatellite instability (MSI) status to exclude the influence of Lynch syndrome. All statistical tests were two-sided.
resultsThe association between CRC family history and non-MSI CRC risk differed statistically significantly by LINE-1 methylation level (P (heterogeneity) = .02). CRC family history was associated with a statistically significantly higher risk of LINE-1 methylation-low non-MSI cancer (multivariable hazard ratio [HR] = 1.68, 95% confidence interval [CI] = 1.19 to 2.38 for 1 vs 0 first-degree relatives with CRC; multivariable HR = 3.48, 95% CI = 1.59 to 7.6 for ≥2 vs 0 first-degree relatives with CRC; P (trend) < .001). In contrast, CRC family history was not statistically significantly associated with LINE-1 methylation-high non-MSI cancer (P (trend) = .35).
conclusionsThis molecular pathological epidemiology study shows that CRC family history is associated with a higher risk of LINE-1 methylation-low CRC, suggesting previously unrecognized heritable predisposition to epigenetic alterations. Additional studies are needed to evaluate tumor LINE-1 methylation as a molecular biomarker for familial cancer risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.